• Mutation; HGNC; HGNC:4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (Patent=US20200384022; PubMed=32229503; PubMed=34732238).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Unspecified (PubMed=32229503; PubMed=34732238).
  

PubMed=28947132; DOI=10.1016/j.yexcr.2017.09.032
Michael Hananja Meel, A. Charlotte P. Sewing, Piotr Waranecki, Dennis S. Metselaar, Laurine E. Wedekind, Jan Koster, Dannis G. van Vuurden, Gertjan J.L. Kaspers, Esther Hulleman;
Culture methods of diffuse intrinsic pontine glioma cells determine response to targeted therapies.
Exp. Cell Res. 360:397-403(2017)

Patent=US20200384022
Mario L. Suva, Bradley E. Bernstein, Aviv Regev, Mariella G. Filbin, Itay Tirosh, Volker Hovestadt;
Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas.
Patent number US20200384022, 10-Dec-2020

PubMed=32229503; DOI=10.1158/1541-7786.MCR-19-0507
Zhao-Hui Wang, Cheng Xu, Bill H. Diplas, Casey Joseph Moure, Chin-Pu Jason Chen, Lee H. Chen, Chang-Zheng Du, Hui-Shan Zhu, Paula K. Greer, Li-Wei Zhang, Yi-Ping He ...Show all 13 authors... , Matthew S. Waitkus, Hai Yan; Show fewer authors
Targeting mutant PPM1D sensitizes diffuse intrinsic pontine glioma cells to the PARP inhibitor olaparib.
Mol. Cancer Res. 18:968-980(2020)

PubMed=34732238; DOI=10.1186/s40478-021-01270-y; PMCID=PMC8565061
Cheng Xu, Heng Liu, Christopher J. Pirozzi, Lee H. Chen, Paula K. Greer, Bill H. Diplas, Li-Wei Zhang, Matthew S. Waitkus, Yi-Ping He, Hai Yan;
TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
Acta Neuropathol. Commun. 9:178.1-178.12(2021)